Arcutis Biotherapeutics Inc. (ARQT) PT Lowered to $57 at Mizuho Securities, Analyst Still Expects a "High Likelihood of a Positive Phase 3 Readout", Maintains Buy Rating
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear lowered the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $57.00 (from $58.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
